J&J “Actively Engaged” Lobbying Against Obama Corporate Tax Provision
This article was originally published in The Pink Sheet Daily
Executive Summary
Repeal of deferral of corporate tax on foreign income is short-sighted, J&J says; company stays mum, though, on Remicade, golimumab negotiations with Merck.
You may also be interested in...
J&J Not Likely To Hold Its Peace At Merck/Schering Altar
Merck and Schering-Plough are talking up the future - the commercial, pipeline and cost savings advantages of a proposed $41.1 billion merger - like newlyweds who have already tied the knot, danced the first dance and cut the cake. But there's an uninvited guest at the affair, Johnson & Johnson, a third-party with bargaining power that could step in to thwart Merck and Schering's happily ever after
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.